FindTrial
Sign In

Case series:CD19 CAR-T

3 trials

Sponsors

Xuanwu Hospital Capital Medical University, The First Affiliated Hospital of Anhui Medical University, Shanghai Sixth People's Hospital

Conditions

B cell malignanciesrefractory and relapsed B-cell acute lymphoblastic leukemia/invasive B-cell non-Hodgkin's lymphomarefractory/relapse B cell lymphoma, acute B lymphoblastic leukemia, and chronic B lymphoblastic leukemia

Unknown Phase

A clinical study using CD19-specific chimeric antigen receptor engineered T cells for the treatment of refractory/relapse B cell lymphoma, acute B lymphoblastic leukemia, and chronic B lymphoblastic leukemia
RecruitingChiCTR1800014761
Xuanwu Hospital Capital Medical Universityrefractory/relapse B cell lymphoma, acute B lymphoblastic leukemia, and chronic B lymphoblastic leukemia
Start: 2018-03-01Updated: 2018-02-05
CD19-targeting CAR T Cells in Relapsed or Refractory B-cell Malignancies
RecruitingChiCTR1800016315
The First Affiliated Hospital of Anhui Medical UniversityB cell malignancies
Start: 2018-06-01Updated: 2018-05-28
A clinical study evaluating CD19 CAR-T in the treatment of refractory and relapsed B-cell acute lymphoblastic leukemia/invasive B-cell non-Hodgkin's lymphoma
Active, not recruitingChiCTR1800019234
Shanghai Sixth People's Hospitalrefractory and relapsed B-cell acute lymphoblastic leukemia/invasive B-cell non-Hodgkin's lymphoma
Start: 2018-12-03Updated: 2018-11-05

Related Papers

Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy
Frontiers in Oncology2022-06-214 citations